Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial.

ABSTRACT:

Objective

To estimate the cost-consequence of treating spasticity early with botulinum toxin in the acute stroke unit.

Design

Secondary cost-consequence analysis, using data from a double-blind randomised-controlled trial.

Setting

Single-centre specialised stroke unit.

Subjects and interventions

Patients with Action Research Arm Test grasp-score of <2 and who developed spasticity within six weeks of a first stroke were randomised to receive injections of: 0.9% sodium-chloride solution (placebo) or onabotulinumtoxin-A (treatment).

Main measures

Resource use costs were calculated for the study. Mean contracture costs for each group were calculated. The Barthel Index and Action Research Arm Test were used to generate a cost per unit of improvement.

Resul

SUBMITTER: Lindsay C 

PROVIDER: S-EPMC9912301 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature